Thank you for Subscribing to Chemical Industry Review Weekly Brief
From Bench Chemist to Biotech Pathfinder
Jason Gatlin’s scientific journey began with hands-on research as an intern at institutions like Harvard and Biogen. His early work on synthesis, purification and encoding libraries laid a foundation for future innovation. His PhD work at the University of Oregon, which resulted in a patented method for synthesizing Keggin-like nanoclusters, revealed a rare talent for translating theoretical chemistry into scalable practice.
Gatlin transitioned into industry, taking on roles at Chemica Technologies and Crystal Clear Technologies, where he led synthesis for contaminant remediation and metal chelation. These foundational years nurtured a systems approach and a keen eye for process optimization.
His decade-long tenure at Sarepta Therapeutics marked a defining period. There, he rose from senior scientist to director of oligonucleotide chemistry and lab services, pioneering high-throughput synthesis and purification for PMO and ASO candidates. Gatlin supervised critical components of RNA/DNA-based drug production, managed up to 35 lab spaces and played a central role in Sarepta’s continued leadership in oligonucleotide-based therapies.
He then joined Tome Biosciences as senior director and chemical hygiene officer, overseeing a new era in gene editing with in-house development of integrase- and ligase-mediated programmable genomic integration systems. His work here focused on both technical synthesis and embedding safety protocols into cutting-edge biotech development.
Driving the R&D Engine with Precision and Passion
Since joining Regeneron in early 2025, Gatlin has taken the helm of RGM R&D Chemistry, a key innovation driver within one of the world’s most forward-thinking biotech firms. His leadership integrates synthetic chemistry, safety and scale-up operations in pursuit of transformative gene-editing treatments.
With tools like Mermade 128AVB, 192x and Cytiva OligoSynt, Gatlin leads synthesis of modified oligonucleotides tailored for high-complexity applications. He aligns upstream and downstream operations to support in vivo validation and tech transfer to external CMOs. His cross-functional fluency ensures that scientific ambition is backed by operational feasibility and regulatory compliance.
A certified Six Sigma practitioner and statistical problem solver, he bridges data insight with technical mastery. Beyond the lab, his decades of volunteer service with Scouting America, reflect a lifelong commitment to growth and stewardship.
As the biotech industry races toward scalable gene editing, Jason Gatlin ensures the path forward is as secure as it is visionary. With every synthesis, every standard operating procedure and every team he builds, he’s laying down a future meant for more.
Gatlin transitioned into industry, taking on roles at Chemica Technologies and Crystal Clear Technologies, where he led synthesis for contaminant remediation and metal chelation. These foundational years nurtured a systems approach and a keen eye for process optimization.
His decade-long tenure at Sarepta Therapeutics marked a defining period. There, he rose from senior scientist to director of oligonucleotide chemistry and lab services, pioneering high-throughput synthesis and purification for PMO and ASO candidates. Gatlin supervised critical components of RNA/DNA-based drug production, managed up to 35 lab spaces and played a central role in Sarepta’s continued leadership in oligonucleotide-based therapies.
He then joined Tome Biosciences as senior director and chemical hygiene officer, overseeing a new era in gene editing with in-house development of integrase- and ligase-mediated programmable genomic integration systems. His work here focused on both technical synthesis and embedding safety protocols into cutting-edge biotech development.
Driving the R&D Engine with Precision and Passion
Since joining Regeneron in early 2025, Gatlin has taken the helm of RGM R&D Chemistry, a key innovation driver within one of the world’s most forward-thinking biotech firms. His leadership integrates synthetic chemistry, safety and scale-up operations in pursuit of transformative gene-editing treatments.
With tools like Mermade 128AVB, 192x and Cytiva OligoSynt, Gatlin leads synthesis of modified oligonucleotides tailored for high-complexity applications. He aligns upstream and downstream operations to support in vivo validation and tech transfer to external CMOs. His cross-functional fluency ensures that scientific ambition is backed by operational feasibility and regulatory compliance.
A certified Six Sigma practitioner and statistical problem solver, he bridges data insight with technical mastery. Beyond the lab, his decades of volunteer service with Scouting America, reflect a lifelong commitment to growth and stewardship.
As the biotech industry races toward scalable gene editing, Jason Gatlin ensures the path forward is as secure as it is visionary. With every synthesis, every standard operating procedure and every team he builds, he’s laying down a future meant for more.
